title: Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management.
abstract: BACKGROUND
  The impact of active surveillance, comprising annual computed tomography scanning and bone marrow biopsies, in the follow-up of patients after high-dose therapy with autologous stem cell rescue for recurrent follicular lymphoma was analyzed.
  
  
  METHODS
  Seventy-one of 99 patients who received high-dose therapy commenced the surveillance program. Response duration, time to next treatment and overall survival were compared according to whether disease progression had been diagnosed on the basis of surveillance investigations or on clinical grounds.
  
  
  RESULTS
  After a median follow-up of 16 years, progression was documented by surveillance in 16 patients and clinically in 18, the median response duration being 2.4 and 2.3 years, respectively (P=NS). Ten patients with a relapse detected clinically started treatment immediately, contrasting with one patient whose relapse was detected by surveillance investigations. Five patients with relapses detected by surveillance investigations have not required treatment after a median follow-up of 18 years, whereas all but two patients with a relapse detected clinically have been treated. The median time to next treatment was 7 years for patients with a relapse identified by surveillance investigations and 4 years for those whose relapse was manifested clinically (P=0.03). Overall survival was not significantly different between the two groups.
  
  
  CONCLUSIONS
  Surveillance investigations, consisting of annual computed tomography scanning and bone marrow biopsies, have no impact on the management of patients with recurrent follicular lymphoma and do not improve the outcome of these patients.
authors.affiliation: CR-UK Medical Oncology Unit, St Bartholomew's Hospital, Barts and the London School of Medicine and Dentistry, 45 Little Britain, EC1A 7BE. London, United Kingdom.
authors.forename: Marco
authors.initials: M
authors.lastname: Gerlinger
authors.forename: Ama Z S
authors.initials: AZ
authors.lastname: Rohatiner
authors.forename: Janet
authors.initials: J
authors.lastname: Matthews
authors.forename: Andrew
authors.initials: A
authors.lastname: Davies
authors.forename: T Andrew
authors.initials: TA
authors.lastname: Lister
authors.forename: Silvia
authors.initials: S
authors.lastname: Montoto
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001856:Bone Marrow Examination; D019468:Disease Management; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014054:Tomography; D014182:Transplantation, Autologous